Compile Data Set for Download or QSAR
maximum 50k data
Found 30 of ki for monomerid = 311911
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi:  39.9nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi:  39.9nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi:  39.9nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi:  39.9nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi:  39.9nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi:  39.9nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 3(Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >8.62E+3nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 3(Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >8.62E+3nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 3(Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >8.62E+3nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 3(Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >8.62E+3nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 3(Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >8.62E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 3(Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >8.62E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.15E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.15E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.15E+3nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.15E+3nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.15E+3nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.15E+3nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.60E+3nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.60E+3nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.60E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.60E+3nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.60E+3nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.60E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 5(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.85E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 5(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.85E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 5(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.85E+3nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 5(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.86E+3nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 5(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.86E+3nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 5(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311911(US10166214, Example 47 | US10675268, Example 47 | ...)
Affinity DataKi: >9.86E+3nMAssay Description:The displacement of the labeled ligand by the test compound leads to a decreased signal. For the binding experiments 200 μL of membrane homogena...More data for this Ligand-Target Pair
In DepthDetails US Patent